• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor americanpharmaceuticalreview
    January 17, 2020
    PhaseBio Pharmaceuticals has signed an agreement with Viamet Pharmaceuticals and its wholly-owned subsidiary, Selenity Pharmaceuticals, to acquire all of the assets and intellectual property rights related to certain novel aldosterone synthase inhibitors

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service